Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Review of a promising new agent--pemetrexed disodium Paz-Ares L; Bezares S; Tabernero JM; Castellanos D; Cortes-Funes HCancer 2003[Apr]; 97 (8 Suppl): 2056-63Pemetrexed disodium (ALIMTa, [pemetrexed], LY231514; Eli Lilly and Company; Indianapolis, IN), a novel antifolate antimetabolite with multiple enzyme targets involved in both pyrimidine and purine synthesis, has entered clinical trials due to its favorable pleclinical profile. Many studies utilizing the drug, as a single or combination agent, are currently ongoing, including Phase III trials in mesothelioma, nonsmall cell lung carcinoma (NSCLC) and pancreatic cancer. Promising feasibility and activity data have been obtained with pemetrexed in combination with platinum compounds and gemcitabine. The supplementation with daily oral folate could reduce the incidence of hematologic toxicities while preserving the antitumor activity of pemetrexed.|Animals[MESH]|Antimetabolites, Antineoplastic/adverse effects/*therapeutic use[MESH]|Clinical Trials as Topic[MESH]|Glutamates/adverse effects/*therapeutic use[MESH]|Guanine/adverse effects/*analogs & derivatives/*therapeutic use[MESH]|Humans[MESH]|Lung Neoplasms/*drug therapy/mortality[MESH]|Pancreatic Neoplasms/*drug therapy/mortality[MESH]|Pemetrexed[MESH]|Safety[MESH]|Survival Rate[MESH]|Thymidylate Synthase/antagonists & inhibitors[MESH]|Treatment Outcome[MESH]|Urinary Bladder Neoplasms/*drug therapy/mortality[MESH] |
